A generic medicine indicated for women's health and oncology support. Blocks cellular receptor sites to inhibit the progression of hormone-sensitive cell growth.
Designed to support estrogen receptor blockade to manage breast tumors and alleviate cellular tumor progression.
Mechanism of Action
Competitively binds to estrogen receptors in target tissues, blocking gene transcription in hormone-sensitive cells.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
24 hours
Contraindications
Pregnancy, History of deep vein thrombosis, Concurrent coumarin-type anticoagulants
Severe Adverse Events
Thromboembolism — requires immediate medical attention, Endometrial carcinoma — requires immediate medical attention, Severe retinopathy — requires immediate medical attention
Information related to Nolvadex is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
